Survey: Many docs will be slow to switch to biosimilar mAbs FierceBiotech But there was a distinct hesitancy noted in the U.S. when the conversation turned to the first generation of biosimilars for the monoclonal antibodies like rituximab (Roche's ($RHHBY) $5.6 billion drug MabThera). BioTrends' survey found that close to ... Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 ... |
